Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 1.00 |
| ▸ | LGALS9 | O00182 | 8/20 | 1.00 |
| ▸ | LGALS8 | O00214 | 7/20 | 1.00 |
| ▸ | LGALS7; LGALS7B | P47929 | 7/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 8/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425152 | 1.00 | LGALS3 (1.00) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL13385533 | 0.92 | LGALS3 (0.86) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL3276985 | 0.92 | LGALS3 (0.86) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL16258793 | 0.92 | LGALS3 (0.86) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL13404617 | 0.92 | LGALS3 (0.86) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL13385541 | 0.85 | LGALS3 (0.74) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL13385538 | 0.80 | LGALS3 (0.77) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL13405067 | 0.80 | LGALS3 (0.77) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL3277187 | 0.80 | LGALS3 (0.77) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL13385529 | 0.79 | LGALS3 (0.66) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751172-B1 | NOVEL 3-TRIAZOLYL-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (SE) | 2014-07-09 | — | — | EP | claimed |
| EP-2297174-B1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | GALECTO BIOTECH AB (DK) | 2015-07-08 | — | — | EP | disclosed |
| US-7700763-B2 | 3-triazolyl-galactoside inhibitors of galectins | FORSKARPATENT I SYD AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20070185041-A1 | NOVEL 3-TRIAZOLYL-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185041-A1 | NOVEL 3-TRIAZOLYL-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885LGALS9 7/4885LGALS8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.